Biomedical Research

Objective: To observe the short-term clinical effect of pulmonary wedge resection in the treatment of primary Non-Small Cell Lung Cancer (NSCLC) and its effect on levels of anti-survivin antibody, Hsp90α and CEA in serum of patients.

Methods: 32 cases of elderly patients with stage Ia non-small cell lung cancer were treated with thoracoscopic pulmonary wedge resection from January 2013 to January 2016, and 32 cases of healthy subjects were enrolled as control group. The patient's surgical indicators and the relapse after surgery were followed. The levels of anti-Survivin antibody, Hsp90α and CEA in the serum of the two groups before surgery were compared; the levels of anti-Survivin antibody, Hsp90α and CEA before and after the operation in the serum of the patients were compared.

Results: The operation time was 38~98 min, with an average of 71.7 ± 13.2 min. Intraoperative blood loss was an average of 113.2 ml. No open chest surgery cases. Postoperative pulmonary infection occurred in 4 cases. The levels of anti-survivin antibody, Hsp90α and CEA in the serum of the observation group before surgery were significantly higher than those in the control group (P<0.05). The anti-survivin antibody, Hsp90α and CEA levels in serum of patients after surgery were significantly lower than those before operation (P<0.05). The three indexes of patients with recurrent metastases were significantly higher than those without recurrence and metastasis (P<0.05).

Conclusion: Pulmonary wedge resection is effective in the treatment of elderly patients with stage Ia Non-Small Cell Lung Cancer (NSCLC). The levels of anti-Survivin antibody, Hsp90α and CEA in serum after operation are significantly decreased.

Author(s): Run-hua Tian, Chun-xi Zheng, Rong-rong Dou, Yun-yuan Zhang, Xian Chen
Abstract | Full-Text | PDF

Share this